Francis Medical's VAPOR 2 Trial Shows Strong Early Results for Prostate Cancer Treatment
Event summary
- Francis Medical published initial results from its VAPOR 2 pivotal trial in The Journal of Urology, showing 91% clearance of targeted prostate cancer lesions after a single treatment.
- The study reported no device-related serious adverse events and low rates of urinary incontinence and erectile dysfunction.
- Vanquish Water Vapor Ablation System demonstrated the ability to treat lesions throughout the prostate, including anatomically challenging locations.
- The trial will continue following patients for five years to gather longer-term outcomes for a potential PMA submission.
The big picture
The positive early results from the VAPOR 2 trial position Francis Medical as a key player in the evolving field of minimally invasive prostate cancer treatments. As the industry shifts toward more targeted and less invasive therapies, these findings could accelerate adoption of water vapor ablation among urologists seeking to preserve patient quality of life while effectively treating localized prostate cancer.
What we're watching
- Regulatory Pathway
- Whether the five-year follow-up data will support a successful PMA submission for expanded indications.
- Market Adoption
- The pace at which urologists and patients embrace water vapor ablation as a focal therapy option.
- Competitive Positioning
- How Francis Medical differentiates Vanquish from other emerging focal therapy technologies.